Open AccessThe role of biomarkers of acute kidney injury in predicting functional outcomes of surgical treatment of patients with localized kidney cancer
Author(s) -
И. О. Дементьев,
К. М. Нюшко,
О. Б. Карякин,
В. С. Чайков,
А. В. Троянов,
И. Н. Заборский,
Е. О. Щукина
Publication year - 2021
Publication title -
issledovaniâ i praktika v medicine
Language(s) - English
Resource type - Journals
eISSN - 2410-1893
pISSN - 2409-2231
DOI - 10.17709/2410-1893-2021-8-3-9
Subject(s) - medicine , acute kidney injury , kidney disease , kidney , kidney cancer , biomarker , cystatin c , azotemia , complication , interstitial nephritis , cancer , intensive care medicine , renal function , biochemistry , chemistry
Currently, due to the dynamic development of surgical technologies, indications for organ-sparing treatment of kidney cancer are expanding. Acute kidney injury is a serious complication that leads to chronic kidney disease, increased postoperative mortality, deterioration of long-term functional outcomes, and increased hospitalization. At present, it is known that even a slight damage to kidneys or their impairment, presented by a decreased urine output and change in blood biochemical parameters, entails serious clinical consequences and is associated with a poor prognosis. Damaging factors, when the kidney is exposed, initially induce molecular changes, which entail the production of certain biomarkers, and only after that clinical aspects of kidney damage develop. The causes of acute kidney injury can be different, from specific renal disorders (acute interstitial nephritis, vascular and glomerular lesions, prerenal azotemia, obstructive disorders) to toxic damages, direct trauma and surgical treatment. The development of acute renal injury in the postoperative period is a serious complication of the surgical treatment of kidney disease, and, according to various authors, the frequency of its occurrence varies from 5.5 % to 34 %. An active study of this problem made it possible to find specific biomarkers that give the possibility to predict and diagnose acute renal injury in the early stages, to optimize the treatment strategy, to reduce the incidence of postoperative complications, and to shorten the period of postoperative rehabilitation. Currently, the most studied of acute kidney injury (AKI) biomarkers are cystatin C, neutrophil gelatinase-associated lipocalin‑2 (NGAL), hepatic protein L-FABP, KIM‑1 (Kidney injury molecule‑1), Interleukin – 18. Further study of AKI biomarkers will make it possible to determine the most significant ones for subsequent use in everyday practice